Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quantum Genomics has entered into a partnership agreement with Inserm, the French national institute for health and medical research and Universities Paris Descartes and Paris XII Val-de-Marne to co-develop QGC002, a promising drug candidate for stroke and cardiac ischemia.
Subscribe to our email newsletter
Under the terms of the agreement, Quantum Genomics (QGC) retains the right to acquire the intellectual property generated by Inserm and to exploit associated know-how. QGC will fund and conduct preclinical development and drug manufacturing whereas Inserm’s teams (Unit 549 and Unit 841) will handle pharmacological studies in relevant animal models of the targeted diseases. QGC is aiming to initiate a regulatory pre-clinical development phase in 2009.
The unique mechanism of action of QGC002 suggests it could become the prototype of an anti-ischemic drug with a wide time window of neuroprotection and cardioprotection.
Lionel Segard, chairman and CEO of QGC, said: “This partnership with Inserm provides QGC with a novel first-in-class drug that complements our pipeline.”